Examkin

Question

Difficulty: HardRheumatology and Immunology

A 42-year-old woman is diagnosed with severe, seropositive rheumatoid arthritis characterized by symmetric polyarthritis involving the metacarpophalangeal joints, morning stiffness lasting 2 hours, and bone erosions on radiography. She is preparing to begin long-term pharmacotherapy. Arrange the following clinical steps in the correct chronological sequence according to current consensus guidelines for the escalating management of rheumatoid arthritis.

  1. 1Initiate first-line therapy with oral methotrexate and folic acid.
  2. 2Evaluate the clinical response at 3 months, documenting persistently high disease activity.
  3. 3Perform an interferon-gamma release assay to screen for latent tuberculosis.
  4. 4Prescribe a tumor necrosis factor (TNF) inhibitor as add-on therapy.
  5. 5Switch to an alternative mechanism biologic (e.g., anti-IL-6 or anti-CD20) if symptoms persist after 6 months.

Answer

The correct chronological sequence is: initiate methotrexate, evaluate the clinical response at 3 months, perform an interferon-gamma release assay, prescribe a TNF inhibitor, and finally switch to an alternative mechanism biologic if the TNF inhibitor fails.
Rheumatoid arthritis management follows a strict algorithmic escalation. Methotrexate is the universal first step. Because csDMARDs require time to work, a 3-month evaluation is necessary before deciding on failure. If the disease remains active, biologic escalation is warranted. However, the initiation of any biologic (especially TNF inhibitors) requires immediate prior screening for latent tuberculosis and hepatitis B/C to prevent fatal reactivation. Once cleared, the TNF inhibitor is added. Finally, if the patient fails the TNF inhibitor trial, standard practice is to switch to a biologic with a different mechanism of action rather than cycling through another TNF inhibitor.

Step-by-Step Solution

1
Identify the standard first-line pharmacotherapy for a new diagnosis of severe rheumatoid arthritis.
The first step is initiating methotrexate alongside folic acid supplementation.
Methotrexate is the most effective initial csDMARD, serves as the anchor drug for rheumatoid arthritis, and reduces the risk of anti-drug antibodies if biologics are used later.
2
Determine the appropriate timeframe for evaluating the initial therapy.
The second step is evaluating the patient at a 3-month follow-up.
Conventional DMARDs take several months to reach full efficacy; premature escalation before an adequate trial should be avoided.
3
Recognize the required safety prerequisites before escalating to biologic therapy.
The third step is performing an interferon-gamma release assay (IGRA).
Biologics strongly increase the risk of tuberculosis reactivation, making infectious screening a mandatory chronological gatekeeper before their initiation.
4
Select the appropriate next line of therapy following csDMARD failure.
The fourth step is prescribing a TNF inhibitor as an add-on therapy.
Adding a biologic DMARD to background methotrexate is the standard of care for methotrexate non-responders.
5
Determine the management strategy if the initial biologic fails.
The final step is switching to an alternative mechanism biologic.
Patients who do not respond to a TNF inhibitor are typically transitioned to a biologic with a different mechanism of action, such as an IL-6 inhibitor or CD20 monoclonal antibody.

Key Concept

The stepwise escalation of pharmacotherapy in rheumatoid arthritis emphasizes initial csDMARD use, mandatory infectious screening immediately prior to biologic therapy, and class-switching upon primary biologic failure.
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic